• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Flat; Initial Jobless Claims Fall To 210,000

    3/28/24 10:32:43 AM ET
    $AVTX
    $BDRX
    $GMDA
    $KOD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday.

    Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.

    Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 0.7% on Thursday.

    In trading on Thursday, information technology shares fell by 0.2%.

     

    Top Headline

     

    U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000.

     

    Equities Trading UP

     

    Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares shot up 435% to $24.91 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.

    Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) got a boost, surging 154% to $1.62 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.

    Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares were also up, gaining 92% to $1.65. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers.

     

    Equities Trading DOWN

     

    Primech Holdings Ltd. (NASDAQ:PMEC) shares dropped 49% to $1.98 after the company issued financial updates and corporate highlights for the six months ended Sept. 30, 2023.

    Shares of Gamida Cell Ltd. (NASDAQ:GMDA) were down 27% to $0.0434. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.

    Kodiak Sciences Inc. (NASDAQ:KOD) was down, falling 24% to $5.63 after the company reported a wider-than-expected fourth-quarter loss.

    Also Check This Out: Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer

     

    Commodities

     

    In commodity news, oil traded up 1.2% to $82.34 while gold traded up 0.6% at $2,226.90.

    Silver traded down 0.2% to $24.70 on Thursday, while copper fell 0.2% to $3.9905.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.2%, London’s FTSE 100 rose 0.4% while Spain’s IBEX 35 Index fell 0.1% The German DAX rose 0.1% French CAC 40 rose 0.1% while Italy’s FTSE MIB Index rose 0.1%.

    Bank lending to households in the Eurozone rose by 0.3% year-over-year to €6.87 trillion in February. The manufacturing confidence index in Italy climbed to 88.6 in March versus a revised reading of 87.5 in the prio month. German jobless rate came in steady at 5.9% in March, while German retail sales fell by 1.9% month-over-month for February.

    The British economy shrank by 0.2% year-over-year during the fourth quarter, while current account gap in the UK widened to £21.2 billion in the fourth quarter of 2023 versus a revised £18.5 billion gap in the prior period. UK car production climbed 14.6% year-over-year to 79,907 units in February.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Thursday, with Japan’s Nikkei 225 falling 1.46%, Hong Kong’s Hang Seng Index gaining 0.91%, China’s Shanghai Composite Index gaining 0.59% and India’s S&P BSE Sensex gaining 1.4%.

    Singapore bank loans rose to SGD 801.5 billion in February from SGD 794.3 billion in the prior month. The Domestic Supply Price Index in Singapore fell 2.8% year-over-year for February.

     

    Economics

     

    The U.S. economy grew an annualized 3.4% in the fourth quarter, up from 3.2% previously reported.

    U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000.

    The Chicago PMI declined to 41.4 in March from 44 in the previous month.

    U.S. pending home sales climbed by 1.6% from the prior month in February versus a revised 4.7% decline in the prior month.

    The University of Michigan consumer sentiment rose to 79.4 in March versus a preliminary reading of 76.5.

    Now Read This: $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BDRX
    $GMDA
    $KOD

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Kodiak Sciences Inc
    $KOD
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    Kodiak Sciences Inc
    $KOD
    9/22/2025$15.00Buy
    Jefferies
    More analyst ratings

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Primech Holdings Accelerates U.S. Expansion for Primech AI's Hytron, Selected for SelectUSA Tech Amid Growing Institutional Deployment Pipeline

    SINGAPORE, April 23, 2026 (GLOBE NEWSWIRE) -- Primech Holdings Limited (NASDAQ:PMEC) ("Primech" or the "Company"), through its autonomous robotics subsidiary Primech AI Pte. Ltd., today announced the acceleration of its U.S. expansion strategy, supported by its selection for the SelectUSA Tech program and participation in the 2026 SelectUSA Investment Summit (May 3–6, 2026, National Harbor, Maryland) following an invitation from the U.S. Embassy in Singapore. This acceleration positions Primech to capitalize on intensifying enterprise demand for AI-powered facility automation and supports the Company's long-term growth strategy through institutional-scale commercial deployment in the world

    4/23/26 7:13:00 AM ET
    $PMEC
    Diversified Commercial Services
    Consumer Discretionary

    Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

    XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models  Consistent with Xilio's clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2 (CLDN18.2), at the American Association for Cancer Research (AACR) Annual Meeting, taking place from A

    4/17/26 4:01:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

    WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct

    4/16/26 7:30:00 AM ET
    $ANIK
    $XLO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Kodiak Sciences Inc

    DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)

    4/22/26 4:18:39 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Kodiak Sciences Inc

    DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)

    4/22/26 4:14:10 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    4/16/26 7:35:16 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Blanchard Cheryl R

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    4/16/26 5:12:22 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Blanchard Cheryl R

    3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    4/16/26 5:11:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    4/16/26 5:00:16 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

    WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct

    4/16/26 7:30:00 AM ET
    $ANIK
    $XLO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

    3/23/26 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Financials

    Live finance-specific insights

    View All

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

    Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

    2/12/25 7:35:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

    2/12/25 7:33:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care